{
  "first_published_at": "2009-03-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088115", 
  "title": "Atomoxetine: risk of psychotic or manic symptoms", 
  "tags": "{\"parsed_therapeutic\": [\"paediatrics-neonatology\", \"psychiatry\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Paediatrics and neonatology\", \"Psychiatry\"]}", 
  "_document_number": 270, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "paediatrics-neonatology", 
    "psychiatry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Atomoxetine: risk of psychotic or manic symptoms</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: March 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children and adolescents without a history of such disorders. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Atomoxetine (Strattera) is a selective noradrenaline reuptake inhibitor, authorised since 2004 for use in the treatment of attention-deficit/hyperactivity disorder (ADHD) as part of a comprehensive treatment regimen.</p><p>Continued case reports of possible nervous-system and psychiatric adverse effects prompted a review of data from all sources, resulting in updated information on the risk of new-onset or worsening of serious psychiatric disorders, including psychotic reactions, hallucinations, mania, and agitation. <a href=\"http://www.medicines.org.uk/emc/\" target=\"_blank\">Product information</a> for prescribers has been updated to reflect more fully the emerging safety information.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania, or agitation) in children and adolescents without a history of psychotic illness or mania</li>\r\n\t\t\t\t<li>If such symptoms occur, consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment</li>\r\n\t\t\t\t<li>It remains possible that atomoxetine might exacerbate pre-existing psychotic or manic symptoms</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><p><em>Article citation: Drug Safety Update March 2009, vol 2 issue 8: 4.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Atomoxetine (Strattera) is a selective noradrenaline reuptake inhibitor, authorised since 2004 for use in the treatment of attention-deficit/hyperactivity disorder (ADHD) as part of a comprehensive treatment regimen.</p><p>Continued case reports of possible nervous-system and psychiatric adverse effects prompted a review of data from all sources, resulting in updated information on the risk of new-onset or worsening of serious psychiatric disorders, including psychotic reactions, hallucinations, mania, and agitation. <a href=\"http://www.medicines.org.uk/emc/\" target=\"_blank\">Product information</a> for prescribers has been updated to reflect more fully the emerging safety information.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania, or agitation) in children and adolescents without a history of psychotic illness or mania</li>\r\n\t\t\t\t<li>If such symptoms occur, consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment</li>\r\n\t\t\t\t<li>It remains possible that atomoxetine might exacerbate pre-existing psychotic or manic symptoms</li>\r\n\t\t\t</ul></div><p>&#160;</p><p><em>Article citation: Drug Safety Update March 2009, vol 2 issue 8: 4.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-03-01", 
  "date_last_modified": "2010-08-05", 
  "_assets": [], 
  "_item_id": 270, 
  "summary": "Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children and adolescents without a history of such disorders. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment", 
  "body": "Article date: March 2009\n\nAtomoxetine (Strattera) is a selective noradrenaline reuptake inhibitor, authorised since 2004 for use in the treatment of attention-deficit/hyperactivity disorder (ADHD) as part of a comprehensive treatment regimen.\n\nContinued case reports of possible nervous-system and psychiatric adverse effects prompted a review of data from all sources, resulting in updated information on the risk of new-onset or worsening of serious psychiatric disorders, including psychotic reactions, hallucinations, mania, and agitation. [Product information](http://www.medicines.org.uk/emc/) for prescribers has been updated to reflect more fully the emerging safety information.\n\nAdvice for healthcare professionals:  \n  \n  * At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania, or agitation) in children and adolescents without a history of psychotic illness or mania  \n  * If such symptoms occur, consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment  \n  * It remains possible that atomoxetine might exacerbate pre-existing psychotic or manic symptoms  \n  \nÂ \n\nArticle citation: Drug Safety Update March 2009, vol 2 issue 8: 4.\n"
}